Aminoquinoline derivatives and their use as adenosine a3 ligands
CA 2448561 C · Owner: Sanofi-Synthelabo · Inventors: Kapui, Zoltan; Mikus, Endre; Bata, Imre
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides compounds of general formula (I), (see formula I) , wherein R4 and R5 form together an 1,3-butadienyl group optionally substituted by a methylenedioxy group or one or more straight or branched C1-4 alkyl group straight or , branched C1-4 alkoxy group hydroxy group or halogen atom. , The compounds of the invention are strong adenosine A3 receptor ligands preferably antagonists.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 29, 2002 and granted July 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.